Semax
Semax
Semax is a synthetic analogue of the ACTH hormone fragment, with research demonstrating potent effects on brain-derived neurotrophic factor (BDNF) and cognitive performance. Human clinical studies show significant improvements in selective attention, working memory and information processing speed, without sedation or the dependency associated with conventional cognitive compounds. Semax is registered as a licensed neuroprotective pharmaceutical in Russia and Ukraine, approved for use in stroke recovery, traumatic brain injury and cognitive disorders.
Supplied as research-grade lyophilised peptide. Available in vial, pen and nasal spray formats. For research purposes only.
Research Stack Builder
Build Your Research Stack
Curated combinations based on what researchers actually stack — backed by published data, priced to save.
Stack with Semax
Why researchers stack these
- 01BDNF stimulation balanced by GABA modulation
- 02Cellular energy substrate for cognition
- 03Mitochondrial neurometabolic support
Full research context
Semax drives BDNF upregulation and cortical processing speed — registered as a pharmaceutical in Russia. Selank provides the anxiolytic complement through GABA modulation and neuroimmune pathways, reducing the stress-induced interference that can blunt cognitive enhancement without causing sedation. NAD+ is the cellular energy co-factor that enhanced neuronal activity depletes. MOTS-c adds mitochondrial AMPK activation in neural tissue, supporting the sustained energy demands of improved cognitive function.
Recovery & Repair Protocol
The most studied peptide combination for tissue repair, injury recovery & musculoskeletal healing
Why researchers stack these
- 01Non-competing structural repair pathways
- 02BPC-157 angiogenesis + TB-500 satellite cell activation
- 03GHK-Cu adds the extracellular matrix layer both lack
Full research context
BPC-157 and TB-500 are the two most frequently co-researched repair peptides in published literature, acting through complementary mechanisms — BPC-157 via nitric oxide pathways and angiogenesis, TB-500 via actin-sequestering and satellite cell activation. GHK-Cu rounds out the stack by supporting collagen synthesis and the extracellular matrix that both compounds do not directly address, while reducing the oxidative load that slows tissue recovery.
Metabolic & Body Recomposition
Most popular Peptide Pal stack — two non-competing fat loss axes with skin integrity support
Why researchers stack these
- 01GLP-1 triple agonism + GH axis — two distinct fat loss pathways
- 02Skin integrity preserved throughout recomposition
- 03Most purchased together on Peptide Pal
Full research context
Retatrutide and Tesamorelin address body composition through two non-competing mechanisms. Retatrutide's triple receptor agonism drives broad metabolic improvement and appetite regulation; Tesamorelin is FDA-approved for visceral adipose reduction through the growth hormone axis — a distinct mechanism. GHK-Cu supports skin integrity during recomposition; rapid fat loss without collagen support produces visible skin laxity that is far harder to address after the fact.
Cognitive Performance Stack
Neuropeptides studied for synergistic cognitive enhancement, focus & stress resilience — no sedation
Why researchers stack these
- 01BDNF stimulation balanced by GABA modulation
- 02Focus without anxiety — three non-competing pathways
- 03NAD+ fuels the neuronal energy demand
Full research context
Semax and Selank are registered pharmaceuticals with distinct mechanisms. Semax drives BDNF upregulation and cortical processing speed; Selank reduces the stress-induced cognitive interference that can blunt that effect, without sedation or dependency. NAD+ provides the cellular energy substrate that enhanced neuronal activity demands — researchers consistently report that this combination delivers balanced cognitive performance that neither compound achieves alone.
Skin & Glow Protocol
Collagen synthesis, antioxidant protection & melanin research in one comprehensive skin stack
Why researchers stack these
- 01Collagen, antioxidant & pigmentation — three skin pillars
- 02Tyrosinase inhibition counterbalances MC1R agonism for pathway research
- 03Structural integrity maintained alongside brightening
Full research context
GHK-Cu stimulates collagen synthesis and modulates over 4,000 genes involved in skin repair and inflammatory control — addressing the structural layer. Glutathione reduces oxidative stress and inhibits tyrosinase, producing measurable skin brightening with 30–35% tissue GSH increases confirmed in human RCTs. MT2 drives eumelanin synthesis via MC1R agonism, and researchers frequently combine it with Glutathione to study the interplay between melanocortin-driven pigmentation and tyrosinase inhibition simultaneously. Together these three represent the most comprehensive skin research protocol available.
Cellular Longevity Protocol
Three compounds that decline together with age — combined restoration for mitochondrial & cellular health
Why researchers stack these
- 01All three decline together with age — parallel restoration
- 02Mitochondrial energy, AMPK signalling & antioxidant protection
- 03Most complete cellular longevity protocol available
Full research context
NAD+, MOTS-c, and glutathione all decline measurably with age through parallel but distinct pathways. NAD+ restores sirtuin and PARP function essential for mitochondrial biogenesis and DNA repair — declining up to 50% by age 60. MOTS-c is the mitochondria-derived peptide that activates AMPK signalling and declines alongside NAD+; their combined restoration is the most researched longevity intervention. Glutathione provides the antioxidant protection that prevents cellular damage during the heightened metabolic activity that NAD+ and MOTS-c restoration drives — completing what researchers describe as the foundational cellular longevity triad.
Research & Studies
Peer-reviewed research supporting Semax
Semax Displays Nootropic Activity and Improves Cognitive Performance in Human Subjects
A human clinical study evaluated Semax across measures of selective attention, working memory, and information processing speed before and after administration. Semax-treated participants demonstrated statistically significant improvements in attention task accuracy and processing speed, providing direct human evidence for the nootropic activity previously observed in animal models. Crucially, Semax produced cognitive benefits without sedation, anxiolytic blunting, or the tolerance associated with classical stimulants — suggesting a mechanistically distinct pathway via ACTH receptor modulation, downstream BDNF upregulation, and cortical circuit enhancement that forms part of the evidence base for its registered pharmaceutical status in Russia and Ukraine.
Semax ACTH Analogue Activity and BDNF / TrkB Modulation in Neuroprotection Research
Semax administration significantly upregulated both BDNF (brain-derived neurotrophic factor) and its TrkB receptor expression in hippocampal regions, identifying a neurotrophic mechanism that complements the compound’s ACTH-derived receptor activity. BDNF upregulation is directly associated with improved synaptic plasticity, enhanced learning and memory consolidation, and neuroprotection against ischaemic and excitotoxic damage. These mechanistic findings support Semax’s clinical use as a neuroprotective pharmaceutical in Russia and Ukraine for post-stroke recovery, traumatic brain injury sequelae, and cognitive disorders.